IQVIA Holdings Inc. $IQV Position Lifted by Simplify Asset Management Inc.

Simplify Asset Management Inc. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 92.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,418 shares of the medical research company’s stock after acquiring an additional 8,374 shares during the quarter. Simplify Asset Management Inc.’s holdings in IQVIA were worth $3,926,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IQV. Boston Partners bought a new position in shares of IQVIA in the 3rd quarter worth about $676,698,000. AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Citigroup Inc. lifted its position in shares of IQVIA by 108.2% in the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after buying an additional 475,557 shares during the last quarter. Invesco Ltd. lifted its position in shares of IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after buying an additional 367,204 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of IQVIA by 41.6% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,132,072 shares of the medical research company’s stock worth $255,180,000 after buying an additional 332,505 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. BMO Capital Markets set a $250.00 price target on shares of IQVIA in a research report on Friday, February 6th. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. UBS Group dropped their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $225.69.

IQVIA Stock Up 0.2%

IQV stock opened at $168.28 on Monday. The stock has a market cap of $28.09 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm’s 50-day simple moving average is $169.72 and its 200 day simple moving average is $197.45. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.